Gene · 7468
Papers2,351
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,351
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| NSD2 mediates NF-κB and matrix metalloproteinases to drive hepatocellular carcinoma malignant progression. | Transl Cancer Res | 2025 | 41234869 | PubTator, text mining | PubMed |
| Pathways to precision medicine in cervical cancer: a comprehensive review of small molecule inhibitors, biomarkers and computational approaches. | 3 Biotech | 2025 | 41113926 | PubTator, text mining | PubMed |
| Implications of canonical histone H3.1 and histone variant H3.3 in cancer. | Open Biol | 2025 | 40987316 | PubTator, text mining | PubMed |
| Mechanisms and Pathological Significance of Liquid-Liquid Phase Separation in Bacteria. | FASEB J | 2025 | 40985478 | PubTator, text mining | PubMed |
| Generation of human induced pluripotent stem cell lines derived from Wolf-Hirschhorn syndrome patients with chromosomal 4p deletion. | Hum Cell | 2025 | 40971060 | PubTator, text mining | PubMed |
| Plasma Circular RNAs in Breast Cancer: From Biomarker Potential to Functional Significance. | Cancer Rep (Hoboken) | 2025 | 40965819 | PubTator, text mining | PubMed |
| Structural and Molecular Insight into the PWWP1 Domain of NSD2 from the Discovery of Novel Binders Via DNA-Encoded Library Screening. | ACS Med Chem Lett | 2025 | 40959233 | PubTator, text mining | PubMed |
| Discovery of a novel class NSD2 inhibitor for multiple myeloma with t(4;14). | Blood Neoplasia | 2025 | 40949769 | PubTator, text mining | PubMed |
| SETD2 suppresses tumorigenesis in a KRASG12C-driven lung cancer model, and its catalytic activity is regulated by histone acetylation. | Elife | 2025 | 40948406 | PubTator, text mining | PubMed |
| Comprehensive pan-cancer analysis identified NSD2 as a potential prognostic and diagnostic biomarker. | Cancer Treat Res Commun | 2025 | 40946469 | PubTator, text mining | PubMed |
| Research status of small molecule inhibitors, probes, and degraders of NSDs: a comprehensive review. | Future Med Chem | 2025 | 40926717 | PubTator, text mining | PubMed |
| Successful Identification and Treatment of Cancer of Unknown Primary Originating From Gastric Cancer Using Comprehensive Genomic Profiling and Immune Checkpoint Inhibitor Therapy: A Case Report. | Cancer Rep (Hoboken) | 2025 | 40916582 | PubTator, text mining | PubMed |
| Structural basis of NSD2 degradation via targeted recruitment of SCF-FBXO22. | bioRxiv | 2025 | 40909644 | PubTator, text mining | PubMed |
| CRISPR/Cas9 in colorectal cancer: Revolutionizing precision oncology through genome editing and targeted therapeutics. | Iran J Basic Med Sci | 2025 | 40896696 | PubTator, text mining | PubMed |
| The instrumental role of lipids in governing the sensitivity of multiple myeloma to ferroptosis. | Discov Oncol | 2025 | 40853521 | PubTator, text mining | PubMed |
| The epigenetic circle: feedback loops in the maintenance of cellular memory. | Epigenetics Chromatin | 2025 | 40830515 | PubTator, text mining | PubMed |
| REIIBP methylates nucleolar proteins and regulates pre-rRNA processing. | J Biol Chem | 2025 | 40825508 | PubTator, text mining | PubMed |
| CyTOF profiling of bone marrow immune dynamics across myeloma stages. | Oncoimmunology | 2025 | 40820826 | PubTator, text mining | PubMed |
| Beyond linear: How circRNAs twist and turn Notch signaling. | J Cell Commun Signal | 2025 | 40761890 | PubTator, text mining | PubMed |
| RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications. | MedComm (2020) | 2025 | 40761481 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7468/papers?page=4